Objective:
To summarize recent developments in politics, regulation, and manufacturing within the pharmaceutical industry.
Approach:
- Politics: The European Parliament approved Brexit guidelines for transferring EU agencies from London, with 21 EU member states interested in hosting the EMA.
- Regulation: The EMA adopted a whistleblowing policy to encourage reporting of improprieties, receiving 43 reports since 2013.
- Manufacturing: Mylan recalled faulty EpiPens in the US after an international recall, and GSK recalled nearly 600,000 Ventolin inhalers due to a defect.
Key Findings:
- Senator Claire McCaskill is investigating opioid manufacturers' marketing practices amid rising overdose deaths.
Interpretation:
The article highlights ongoing regulatory and safety issues in the pharmaceutical sector, alongside political developments affecting EU agencies.
Conclusion:
The article provides a snapshot of significant events impacting the pharmaceutical industry, including recalls, investigations, and regulatory changes.
Sources:
- EMA Brexit Guidelines
- Senate Opioid Investigation
- EMA Whistleblowing Policy
- Scott Gottlieb Confirmation Hearing
- Mylan EpiPen Recall
- GSK Ventolin Recall
- Pfizer Strike Resolution
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
